Royalty Pharma plc

RPRX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$1,331$1,700$230$1,241
Dep. & Amort.$0$0$6$23
Deferred Tax$0$0$0$0
Stock-Based Comp.$2$2$2$2
Change in WC$53$5$33-$16
Other Non-Cash$1,382$1,280$1,873$767
Operating Cash Flow$2,769$2,988$2,144$2,018
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions-$11-$13-$10-$35
Inv. Purchases-$2,736-$2,116-$2,565-$3,594
Inv. Sales/Matur.$118$26$1,546$1,776
Other Inv. Act.-$49$29$0-$18
Investing Cash Flow-$2,678-$2,073-$1,029-$1,870
Financing Activities
Debt Repay.$1,471-$1,000$0$1,273
Stock Issued$0$0$0$0
Stock Repurch.-$230-$305$0$0
Dividends Paid-$376-$358-$333-$285
Other Fin. Act.-$504-$486-$612-$602
Financing Cash Flow$361-$2,149-$945$385
Forex Effect$0$0$0$0
Net Chg. in Cash$452-$1,234$170$532
Supplemental Information
Beg. Cash$477$1,711$1,541$1,009
End Cash$929$477$1,711$1,541
Free Cash Flow$2,769$2,988$2,144$2,018
Royalty Pharma plc (RPRX) Financial Statements & Key Stats | AlphaPilot